iLB-MJD1-32m-r9, LB-32-r9
UKBi003-A
General
Cell Line |
|
hPSCreg name | UKBi003-A |
Cite as: | UKBi003-A (RRID:CVCL_W571) |
Alternative name(s) |
iLB-MJD1-32m-r9, LB-32-r9
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
UKBi008-A (iLB-MJD4-34m-r1, LB-34-1) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease UKBi007-A (LB-33-5, iLB-MJD3-33f-r5) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Machado-Joseph disease UNEWi026-A (SF116 clone 1) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UNEWi026-B (SF116 clone 2) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UNEWi026-C (SF116 clone K) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration UCLi006-A (LCMD-L302P-UCL01C2) Donor's gene variants: LMNA Donor diseases: Congenital muscular dystrophy due to LMNA mutation UCLi002-A (HHItC9D-V34, DN19) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Frontotemporal dementia FINi002-A (FI.CPLT.PRKN.R275W+del_e8.PK006) Donor's gene variants: PRKN Donor diseases: Parkinson Disease |
Last update | 4th July 2024 |
User feedback | |
Provider |
|
Generator | Universitätsklinikum Bonn (UKB) |
Owner | Universitätsklinikum Bonn |
Distributors | |
Derivation country | Germany |
External Databases |
|
BioSamples | SAMEA2614075 |
Cellosaurus | CVCL_W571 |
Wikidata | Q54905790 |
General Information |
|
Publications |
|
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 35-39 |
Ethnicity | Caucasian, German |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
Family history | de novo mutation |
External Databases (Donor) |
|
BioSamples | SAMEA2614021 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | No |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Is there other documentation provided to the donor for consenting purposes? | No |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
Does consent permit access to medical records of the donor? | No |
Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Ethik-Komission Rheinische Friederich-Wilhelms-Universität - Medizinische Fakultät |
Approval number | 275/08 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Ethik-Komission Rheinische Friederich-Wilhelms-Universität - Medizinische Fakultät |
Approval number | 275/08 |
Do you have obligations to third parties in regard to the use of the cell line? | Yes |
Please describe: | n/a |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Any skin fibroblast that is part of some dermis.
|
Source cell origin |
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
Age of donor (at collection) | 35-39 |
Collected in | 2008 |
Passage number reprogrammed | P4 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Genes | |
Is the used vector excisable? |
No |
Absence of reprogramming vector(s)? |
Yes |
Reprogramming vectors silenced? |
Yes |
Methods used |
PCR
|
Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Selection criteria for clones | Morphology |
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 21 % |
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|||||
SSEA-3 |
Yes |
|||||
TRA 1-60 |
Yes |
|||||
TRA 1-81 |
Yes |
Differentiation Potency
In vivo teratoma
In vitro directed differentiation
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Certificate of Analysis |
|
Is there a certificate of analysis available? |
Yes
Passage:
28
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
|
Login to share your feedback, experiences or results with the research community.